-

07:53:41 PM

LIVE Real Time JAZZ Stock Market News

JAZZ - Jazz Pharmaceuticals plc

04/20/21 8:45 AM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the "Company") announced today that its wholly owned subsidiary, Jazz Securities Designated Activity Company (the "Issuer"), is commencing a private offering (the "Offering") of senior secured notes (the "Notes") in a

RHEA-AI

neutral

04/20/21 7:45 AM

Nasdaq : JAZZ

Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of Xywav TM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the

RHEA-AI

neutral

04/19/21 4:05 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 first quarter financial results on Tuesday, May 4, 2021 after the close of the financial markets. Company management will host a live audio webcast at 4:30 p.m. ET / 9:30 p.m.

RHEA-AI

neutral

04/12/21 7:45 AM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation and confirmed the acceptance for substantive review of the supplemental New Drug Application (sNDA) seeking

RHEA-AI

neutral

03/30/21 6:15 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos(R) (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved a revised label for Vyxeos (R) (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid

RHEA-AI

neutral

03/22/21 4:05 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the 10th Annual J.P. Morgan Napa Valley Forum.Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a

RHEA-AI

neutral

03/18/21 7:45 AM

Nasdaq : JAZZ

Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and the Hypersomnia Foundation today announced the launch of I Have IH, a disease awareness campaign that aims to increase understanding of the debilitating sleep disorder, idiopathic hypersomnia (IH), and empower

RHEA-AI

neutral

02/23/21 4:10 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Cowen 41st Annual Healthcare conference.Bruce Cozadd, chairman and chief executive officer, will provide an overview of the company and a

RHEA-AI

neutral

02/23/21 4:05 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021. "In 2020, we made meaningful progress toward our goal to significantly grow and diversify 2022

RHEA-AI

positive

02/17/21 4:05 PM

Nasdaq : JAZZ

Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the Leerink 10 th Annual Global Healthcare Conference.Bruce Cozadd, chairman and chief executive officer, will provide an overview of the

RHEA-AI

neutral

JAZZ Chart

JAZZ Data

industryPharmaceutical Preparation Manufacturing
security nameJazz Pharmaceuticals plc
issue typecs
sectorManufacturing
sic code2834
employees1210
tagsHealth Technology,Pharmaceuticals: Other,Manufacturing,Pharmaceutical Preparation Manufacturing
stateWaterloo exchange
cityFifth floor
zipWaterloo Road,Du
countryIreland

JAZZ Description:

Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration approved drug Xyrem , the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid . In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea . In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.